SCHEMBL1889115

SCHEMBL1889115

O=C(Nc1n[nH]c2c1CN(S(=O)(=O)c1cc(F)cc(F)c1)CC2)c1ccncc1NC(=O)[C@H]1CCCO1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.52
LMNA P02545 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42
ALDH1A1 P00352 4/20 0.40
PKM P14618 1/20 0.40
HSD17B10 Q99714 1/20 0.38
MAPK1 P28482 1/20 0.38
MET P08581 1/20 0.38
KDM4E B2RXH2 1/20 0.37
NAMPT P43490 3/20 0.37
POLB P06746 2/20 0.37
DPP4 P27487 1/20 0.35
DPP8 Q6V1X1 1/20 0.35
NPC1 O15118 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1885146 1.00 IGF1R (0.52) IGF1RLMNASMN1; SMN2KMT2AMEN1
SCHEMBL1885148 1.00 IGF1R (0.52) IGF1RLMNASMN1; SMN2KMT2AMEN1
SCHEMBL1889541 0.90 IGF1R (0.54) IGF1RLMNASMN1; SMN2KMT2AMEN1
SCHEMBL1889142 0.90 IGF1R (0.54) IGF1RLMNASMN1; SMN2KMT2AMEN1
SCHEMBL1896236 0.89 IGF1R (0.55) IGF1RKMT2AMETPOLBDPP4
SCHEMBL1889723 0.88 IGF1R (0.52) IGF1RKMT2AMETNAMPTPOLB
SCHEMBL1884610 0.87 IGF1R (0.52) IGF1RLMNASMN1; SMN2KMT2AMEN1
SCHEMBL1894221 0.87 IGF1R (0.52) IGF1RLMNASMN1; SMN2KMT2AMEN1
SCHEMBL1890910 0.87 IGF1R (0.52) IGF1RLMNASMN1; SMN2KMT2AMEN1
SCHEMBL1889052 0.87 IGF1R (0.52) IGF1RLMNASMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173659-B2 Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-05-08 US disclosed
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-09-22 US disclosed
US-7947686-B2 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-24 US disclosed
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-22 US disclosed
EP-1968976-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-09-17 EP disclosed
WO-2007068619-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K3, MAP3K1, MAP3K19 IGF1R 760/4885LMNA 3253/4885SMN1; SMN2 3711/4885
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors MAP3K3, MAP3K1, MAP3K19 IGF1R 760/4885LMNA 3253/4885SMN1; SMN2 3711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.